Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Exenatide LAR once weekly versus insulin glargine once daily in type 2 diabetes
2007-002957-22Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2007
- Modality
- Peptides, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3 trial of exenatide and insulin glargine in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Eli Lilly and Company. Primary endpoints: Change in HbA1c from baseline to week 26, Superiority assessment on HbA1c and 1 more. Started Nov 2007; status: completed.
02
Drugs
exenatideinsulin glargine
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on 2007-002957-22.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-002957-22.